Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elexacaftor/ivacaftor/tezacaftor + ivacaftor - Vertex Pharmaceuticals

Drug Profile

Elexacaftor/ivacaftor/tezacaftor + ivacaftor - Vertex Pharmaceuticals

Alternative Names: Elexacaftor/ivacaftor/tezacaftor - Vertex Pharmaceuticals; ELX/TEZ/IVA; Ivacaftor/tezacaftor/VX 445; Kaftrio; Tezacaftor/VX-445/ivacaftor; TRIKAFTA; TRIKAFTA®; VX 445/ivacaftor/tezacaftor; VX-445/TEZ/IVA; VX-445/VX-661/VX-770

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Antifibrotics; Benzodioxoles; Cyclopropanes; Fluorinated hydrocarbons; Fluorobenzenes; Indoles; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Small molecules; Sulfonamides
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cystic fibrosis

Most Recent Events

  • 18 Jun 2024 Vertex Pharmaceuticals plans a phase III trial for Cystic-fibrosis (In adolesecents, In adults, In the elderly) (PO, Granules) in October 2024 (NCT06460506) (EudraCT2023-509563-24-00)
  • 10 Jun 2024 Adverse events and efficacy data from a phase-III trial in Cystic fibrosis released by Vertex Pharmaceuticals
  • 24 Feb 2024 Vertex Pharmaceuticals completes a phase III trial for Cystic fibrosis (In adolescents, In adults, In children, In the elderly) in USA, Australia, Canada, Ireland, and United Kingdom (PO, Tablet) (NCT04183790) (EudraCT2019-001827-11)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top